Sigma Planning Corp’s Crescent Biopharma CBIO Stock Holding History

Sigma Planning Corp’s Portfolio CBIO Stock Details CBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-180	Closed	-$21K	–	1354
2022 Q1	$21K	Buy	+180	New	+$21.1K	﹤0.01%	1353

Other funds holding CBIO

BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return

NMC

NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Sigma Planning Corp's CBIO Position: Q2 2022 in Review

Sigma Planning Corp sold out of Crescent Biopharma (CBIO) in Q2 2022, closing a stake of 180 shares — an estimated $21K sold.

Sigma Planning Corp first reported a position in CBIO in Q1 2022 and held it in 1 quarter. The position peaked at $21K in Q1 2022. 35 funds tracked by Wall St. Rank hold CBIO as of Q2 2022.

Sigma Planning Corp reported no remaining Crescent Biopharma position as of Q2 2022 after selling out during the quarter.
Sigma Planning Corp sold 180 Crescent Biopharma shares in Q2 2022, an estimated $21K.
Sigma Planning Corp first reported a position in Crescent Biopharma in Q1 2022 and held it in 1 quarter.
Sigma Planning Corp's Crescent Biopharma position peaked at $21K in Q1 2022.
35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2022.

Based on Sigma Planning Corp's 13F filing for Q2 2022, filed 11 Aug 2022.